IS FLOT THE ONLY STANDARD IN THE PREOPERATIVESETTING FOR GASTRIC CANCER?

Andrés CervantesProfessor of Medicine

2

3

4

5

6

7

8

9

10

11

12

FLOT4FLOT COMBINATION Localized gastric and junctional cancer

AL-Batran SE Not yet published2018

ESMO CPG COMMITTEE

X

Median follow up 43 monthsMedian Survival increased by 15 months (35 vs 50 months)Increased survival over control at 3 years: 9%

13Shapiro J, et al. Lancet Oncol 2015; 16:1090-1098.

NEOADJUVANT CHEMORADIATION INESOPHAGEAL CANCER: THE CROSS TRIAL

14Shapiro J, et al. Lancet Oncol 2015; 16:1090-1098.

NEOADJUVANT CHEMORADIATION INESOPHAGEAL CANCER: THE CROSS TRIAL

15Shapiro J, et al. Lancet Oncol 2015; 16:1090-1098.

NEOADJUVANT CHEMORADIATION INESOPHAGEAL CANCER: THE CROSS TRIAL

16

CROSSCARBOPLATIN PACLITAXEL Localized esopahgeal and junctional cancer

SHAPIRO J LANCET ONCOL2015

ESMO CPG COMMITTEE

X

Median follow up 84 monthsMedian Survival increased by 24,6 months (48,6 vs 24 months) GLOBALMedian Survival increased by 16,1 months (43,2 vs 27,1 months) ADCIncreased survival over control at 3 years: 14%

17

Neoadjuvant CT vs CRT: Multicenter propensity-scorematched study

Markar SR, et al. Ann Oncol 2017; 28:518-527.

3-year Overall Survival (57.9% versus 53.4%; HR 0.89, 95%C.I. 0.67–1.17,P<0.391)

18

CROSS versus MAGIG: The neo-AEGIS Trial

Reynolds JV, et al. BMC Cancer 2017; 17:401

19

THANKS